Literature DB >> 20858721

MLH1 founder mutations with moderate penetrance in Spanish Lynch syndrome families.

Ester Borràs1, Marta Pineda, Ignacio Blanco, Ethan M Jewett, Fei Wang, Alex Teulé, Trinidad Caldés, Miguel Urioste, Cristina Martínez-Bouzas, Joan Brunet, Judith Balmaña, Asunción Torres, Teresa Ramón y Cajal, Judit Sanz, Lucía Pérez-Cabornero, Sergi Castellví-Bel, Angel Alonso, Angel Lanas, Sara González, Víctor Moreno, Stephen B Gruber, Noah A Rosenberg, Bhramar Mukherjee, Conxi Lázaro, Gabriel Capellá.   

Abstract

The variants c.306+5G>A and c.1865T>A (p.Leu622His) of the DNA repair gene MLH1 occur frequently in Spanish Lynch syndrome families. To understand their ancestral history and clinical effect, we performed functional assays and a penetrance analysis and studied their genetic and geographic origins. Detailed family histories were taken from 29 carrier families. Functional analysis included in silico and in vitro assays at the RNA and protein levels. Penetrance was calculated using a modified segregation analysis adjusted for ascertainment. Founder effects were evaluated by haplotype analysis. The identified MLH1 c.306+5G>A and c.1865T>A (p.Leu622His) variants are absent in control populations and segregate with the disease. Tumors from carriers of both variants show microsatellite instability and loss of expression of the MLH1 protein. The c.306+5G>A variant is a pathogenic mutation affecting mRNA processing. The c.1865T>A (p.Leu622His) variant causes defects in MLH1 expression and stability. For both mutations, the estimated penetrance is moderate (age-cumulative colorectal cancer risk by age 70 of 20.1% and 14.1% for c.306+5G>A and of 6.8% and 7.3% for c.1865T>A in men and women carriers, respectively) in the lower range of variability estimated for other pathogenic Spanish MLH1 mutations. A common haplotype was associated with each of the identified mutations, confirming their founder origin. The ages of c.306+5G>A and c.1865T>A mutations were estimated to be 53 to 122 and 12 to 22 generations, respectively. Our results confirm the pathogenicity, moderate penetrance, and founder origin of the MLH1 c.306+5G>A and c.1865T>A mutations. These findings have important implications for genetic counseling and molecular diagnosis of Lynch syndrome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20858721     DOI: 10.1158/0008-5472.CAN-10-0570

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study.

Authors:  Mireia Gausachs; Pilar Mur; Julieta Corral; Marta Pineda; Sara González; Llúcia Benito; Mireia Menéndez; Josep Alfons Espinàs; Joan Brunet; María Dolores Iniesta; Stephen B Gruber; Conxi Lázaro; Ignacio Blanco; Gabriel Capellá
Journal:  Eur J Hum Genet       Date:  2012-01-25       Impact factor: 4.246

2.  Confirmed pathogenic effect of a splice site variation in the MLH1 gene causing Lynch syndrome.

Authors:  J L Martín Ruiz; M J Alvarez-Cubero; F Fernandez Rosado; E Martinez Espín; C Entrala Bernal
Journal:  Int J Colorectal Dis       Date:  2014-05-09       Impact factor: 2.571

3.  Prevalence of CNV-neutral structural genomic rearrangements in MLH1, MSH2, and PMS2 not detectable in routine NGS diagnostics.

Authors:  Monika Morak; Verena Steinke-Lange; Trisari Massdorf; Anna Benet-Pages; Melanie Locher; Andreas Laner; Katrin Kayser; Stefan Aretz; Elke Holinski-Feder
Journal:  Fam Cancer       Date:  2020-04       Impact factor: 2.375

Review 4.  Genetic predisposition to colorectal cancer: where we stand and future perspectives.

Authors:  Laura Valle
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

5.  High risk of colorectal and endometrial cancer in Ashkenazi families with the MSH2 A636P founder mutation.

Authors:  Bhramar Mukherjee; Gad Rennert; Jaeil Ahn; Sara Dishon; Flavio Lejbkowicz; Hedy S Rennert; Stacey Shiovitz; Victor Moreno; Stephen B Gruber
Journal:  Gastroenterology       Date:  2011-03-16       Impact factor: 22.682

6.  MLH1 methylation screening is effective in identifying epimutation carriers.

Authors:  Marta Pineda; Pilar Mur; María Dolores Iniesta; Ester Borràs; Olga Campos; Gardenia Vargas; Sílvia Iglesias; Anna Fernández; Stephen B Gruber; Conxi Lázaro; Joan Brunet; Matilde Navarro; Ignacio Blanco; Gabriel Capellá
Journal:  Eur J Hum Genet       Date:  2012-07-04       Impact factor: 4.246

7.  A founder MLH1 mutation in Lynch syndrome families from Piedmont, Italy, is associated with an increased risk of pancreatic tumours and diverse immunohistochemical patterns.

Authors:  Iolanda Borelli; Guido C Casalis Cavalchini; Serena Del Peschio; Monica Micheletti; Tiziana Venesio; Ivana Sarotto; Anna Allavena; Luisa Delsedime; Marco A Barberis; Giorgia Mandrile; Paola Berchialla; Paola Ogliara; Cecilia Bracco; Barbara Pasini
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

8.  Cancer risks and immunohistochemical profiles linked to the Danish MLH1 Lynch syndrome founder mutation.

Authors:  Christina Therkildsen; Anna Isinger-Ekstrand; Steen Ladelund; Anja Nissen; Eva Rambech; Inge Bernstein; Mef Nilbert
Journal:  Fam Cancer       Date:  2012-12       Impact factor: 2.375

9.  Recurrent and founder mutations in the PMS2 gene.

Authors:  J Tomsic; L Senter; S Liyanarachchi; M Clendenning; C P Vaughn; M A Jenkins; J L Hopper; J Young; W Samowitz; A de la Chapelle
Journal:  Clin Genet       Date:  2012-06-04       Impact factor: 4.438

10.  Spectrum of mismatch repair gene mutations and clinical presentation of Hispanic individuals with Lynch syndrome.

Authors:  Annette Y Sunga; Charité Ricker; Carin R Espenschied; Danielle Castillo; Marilena Melas; Josef Herzog; Sarah Bannon; Marcia Cruz-Correa; Patrick Lynch; Ilana Solomon; Stephen B Gruber; Jeffrey N Weitzel
Journal:  Cancer Genet       Date:  2017-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.